Amphastar Pharmaceuticals price to free cash flow AMPH

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026: 7.0×
10-year median: 21.6×
Against its 10-year history: 6th; percentile: 0 is its lowest day, 100 its highest
10-year range: 5.5× to 325×
Peer median: 8.9×

Amphastar Pharmaceuticals' price to free cash flow is 7.0× as of Oct 23, 2026.

That is below its ten-year median of 21.6×, lower than on 94% of days in the last ten years.

Over that time it ranged from 5.5× in May 2026 to 325× in Jan 2020.

The median for 10 large drugmakers of a similar size is 8.9×.

Price to free cash flow over time

median 21.6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.0×	5.5×	11.9×
2025	11.0×	6.5×	12.7×
2024	10.7×	10.7×	21.5×
2023	21.2×	15.5×	59.0×
2022	15.1×	14.7×	36.8×
2021	25.0×	16.4×	71.9×
2020	73.0×	65.8×	325×
2019	311×	32.5×	318×
2018	212×	71.9×	225×
2017	76.6×	32.3×	87.7×
2016	87.8×	56.0×	394×
2015	433×	45.0×	471×

Against its peers

Companies in Drug Manufacturers - General nearest Amphastar Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
AMPHAmphastar Pharmaceuticals	7.0×
OMEROmeros	n/m
ABUSArbutus Biopharma	n/m
PCRXPacira BioSciences	8.1×
ANABAnaptysbio	n/m
COLLCollegium Pharmaceutical	2.3×
PAHCPhibro Animal Health	160×
ANIPANI Pharmaceuticals	9.6×
CRMDCorMedix	2.4×
ZVRAZevra Therapeutics	17.9×
IRWDIronwood Pharmaceuticals	n/m
Peer median	8.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Amphastar Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.